Join | Donations | Contact Us | Print Page | Sign In
Hyperkalemia and Heart Failure: Identifying Risks and Exploring Treatment Options
Register Tell a Friend About This EventTell a Friend
 

This session reviews the impact of elevated potassium as an impediment to the optimization of RAAS Inhibition. Learn how to manage Hyperkalemia in the Heart Failure Patient and explore treatment options.

 Export to Your Calendar 2/6/2018 to 2/5/2019
When: Tuesday, February 6, 2018
Where: Recorded Session
United States
Contact: Gail Haas
856-642-4203


Online registration is available until: 2/6/2019
« Go to Upcoming Event List  

Hyperkalemia and Heart Failure:  Identifying Risks and Exploring Treatment Options

Enduring Activity

Expiration Date: February 2019

1.0 Contact Hour ANCC

 

View Content

 

 

Learner Outcomes:

  • Describe the prevalence and causes of hyperkalemia, its association with adverse clinical outcomes and patient populations at risk for developing hyperkalemia.
  • Discuss the development of hyperkalemia in HF patients who are taking RAAS inhibitors.
  • Explain the relationship of hyperkalemia-related discontinuation/suboptimal dosing of RAAS inhibitors in  heart failure patients to increased cardiovascular risk
  • Recognize goals and implement prudent strategies for managing acute, subacute/intermediate, and chronic hyperkalemia
  • Assess the mechanisms of action, pharmacodynamic profiles, efficacy, and safety of potassium bind for the treatment of hyperkalemia in patients with HF.
  • Recognize the roles and clinical settings for new and emerging agents for treatment of hyperkalemia in heart failure patients.

REQUIREMENT FOR SUCCESSFUL COMPLETION

  1. Attendance at the entire event.
  2. Complete/submit evaluation form.
  3. Access and print your certificate.

PLANNING COMMITTEE 

Maureen Flattery, NP
Planning committee members have no conflicts of interest that relate to this activity.

FACULTY
The following faculty have no conflicts of interest that relate to this activity
Chris Bell, ACNP

The faculty below has disclosed the following
Paul Hauptman, MD, Grants: Alnylam, NHLBI, Relypsa, BMS, Speaker Bureau: Otsuka, Relypsa, Consultant: St Jude Medical, Sunshine Medical, Corvia

ACCREDITATION STATEMENT
This activity is provided by the American Association of Heart Failure Nurses (AAHFN).

The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLAIMER
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

COMMERCIAL SUPPORT

Commercial support for this activity has been provided by CZ Pharma.

 

 

AAHFN is professionally managed by Association Headquarters Inc., a charter accredited association management company.